Selenium-containing compounds and their use in treating neurodegenerative diseases

The anti-Aβ amyloid hyperagglomeration and the like are solved by using specific compounds of formula I, such as 2-(benzolamino)-N-(4-bromophenyl)-1,3-selenazole-5-formamide, etc. The treatment of neurodegenerative diseases has achieved significant pathological improvement effects.

CN112079794BActive Publication Date: 2024-11-12MEDSPRING INT LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201910507260.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-06-12
Publication Date
2024-11-12
Estimated Expiration
2039-06-12

AI Technical Summary

Technical Problem

The prior art lacks effective drugs for treating neurodegenerative diseases, especially Alzheimer's, Parkinson's, and Huntington's, and there are limited methods to combat Aβ amyloid hyperaggregation.

Method used

A drug containing a specific compound of formula I, such as 2-(benzolamino)-N-(4-bromophenyl)-1,3-selenazole-5-formamide and other compounds, and pharmaceutically acceptable. Accepted salts, solvents or prodrugs are used to inhibit excessive aggregation of Aβ amyloids and thus to treat neurodegenerative diseases.

Benefits of technology

These compounds significantly inhibit the excessive aggregation of Aβ amyloids, have neuroprotective effects, and are suitable for the treatment of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Huntington's disease, significantly improving the pathological status of model animals .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112079794B_ABST
    Figure CN112079794B_ABST
Patent Text Reader

Abstract

The present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof. The present invention also relates to a method for preparing the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, a pharmaceutical composition containing the compound and its use in preparing a drug, wherein the drug is used to treat neurodegenerative diseases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to selenium-containing compounds and their use in treating neurodegenerative diseases, and also to a method for preparing the compounds or their pharmaceutically acceptable salts, solvates or prodrugs, a pharmaceutical composition containing the compounds and their use in preparing drugs. Background Art

[0002] Neurodegenerative diseases are irreversible neurological diseases characterized by delayed onset and selective neuronal dysfunction, caused by the loss of neurons in the brain and spinal cord. They mainly include Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). The clinical manifestations of these diseases are all cognitive decline. Although they have different histopathological characteristics, they may have common cellular and molecular mechanisms. Since most neurodegenerative diseases still lack effective treatments, the development of specific therapeutic drugs will become the premise and basis for effectively preventing the occurrence and development of the disease and effectively treating it, which has important theoretical and practical significance for improving the quality of life and life expectancy of the elderly.

[0003] Alzheimer's disease (AD) is a typical representative of neurodegenerative diseases. It was first discovered by German psychiatrist and neuropathologist Alois Alzheimer in 1907. It is a disease caused by degeneration of the central nervous system, and its incidence increases with age. The clinical phenotype of AD is characterized by the gradual decline of two or more cognitive areas, which usually involve episodic memory and behavioral functions, causing personal and social damage. Excessive aggregation of Aβ amyloid and hyperphosphorylated tau neuronal tangles are the main pathological features of AD. In addition, damage and loss of synapses in brain tissue also affect the degree of dementia in AD patients. In many AD cases, excessive aggregation of Aβ amyloid also leads to amyloid cerebrovascular disease and hemorrhagic stroke. Therefore, effectively combating excessive aggregation of Aβ amyloid is an effective treatment for Alzheimer's disease and neurodegenerative diseases.

[0004] There remains a need in the art for different effective drugs for treating neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease and Huntington's disease. Summary of the invention

[0005] The inventors unexpectedly found that the compound of formula I as defined below can effectively combat excessive Aβ amyloid aggregation, thereby providing the use of the compound for treating neurodegenerative diseases including Alzheimer's disease, Parkinson's disease and Huntington's disease and a pharmaceutical composition.

[0006] Specifically, the present invention provides the use of the following compound of formula I or its pharmaceutically acceptable salt, solvate or prodrug for treating neurodegenerative diseases:

[0007]

[0008] Among them, R 1 is H, halogen, unsubstituted or substituted 1-8C alkyl, unsubstituted or substituted benzene ring or naphthalene ring, or unsubstituted or substituted aromatic heterocycle or aromatic condensed heterocycle containing 1-3 ring heteroatoms selected from oxygen, nitrogen and sulfur, wherein the substituent is unsubstituted or substituted 1-3C alkyl, unsubstituted or substituted 1-3C alkoxy, unsubstituted or substituted 1-3C alkyl phenyl, unsubstituted or substituted 1-3C alkyl benzyl, or halogen;

[0009] n is 0, 1 or 2;

[0010] R 2 and R 3 R is independently hydrogen, 1-8C alkyl which is unsubstituted or substituted by 1-3C alkyl, 1-8C alkoxy which is unsubstituted or substituted by 1-3C alkyl, an electron withdrawing group, halogen, phenyl or naphthyl which is unsubstituted or substituted by 1-3C alkyl, or 2 and R 3 Together with the adjacent benzene ring, it forms an unsubstituted or 1-3C alkyl-substituted naphthalene ring or benzo-1,3-dioxolane.

[0011] The 1-8C alkyl group includes straight-chain and branched alkyl groups, such as methyl, ethyl, propyl, isopropyl and tert-butyl, and also includes (3-8C) cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0012] Among them, 1-8C alkoxy includes methoxy, ethoxy, propoxy, isopropoxy and butoxy and the like.

[0013] Among them, the aromatic heterocycle refers to a heteroaromatic ring group with 5-18, preferably 5-14, more preferably 5-10 members, which has one or more ring heteroatoms independently selected from N, O and S, including but not limited to pyridyl, pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, benzofuranyl, carbazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, purinyl, phenothiazinyl, phenoxazolyl, etc. Preferably, the aromatic heterocycle is a 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heteroaromatic ring, such as furanyl, pyrrolyl, thienyl, pyridinyl.

[0014] The aromatic fused heterocycle refers to a heteroaromatic ring group of 5 to 18 carbon atoms having two or more fused rings, which has one or more ring heteroatoms independently selected from N, O and S, including but not limited to indolyl, benzimidazolyl, etc.

[0015] The electron-withdrawing group includes acyl, aldehyde, carboxyl, amido, sulfonic acid, nitrile, nitro, haloform, quaternary amino, etc., preferably nitro.

[0016] Herein, halogen refers to fluorine, chlorine, bromine or iodine. The term "halogen" as used herein may also include their isotopic forms.

[0017] As used herein, the term "pharmaceutically acceptable" generally refers to those that can be used in pharmacy or medicine, or although they cannot be used directly in pharmacy or medicine, they can be used as intermediates for the preparation of pharmaceutical or medical products, and are removed by appropriate methods before they are finally used in pharmacy or medicine. For example, pharmaceutically acceptable salts include not only pharmaceutical salts that can be used in clinical practice, but also salts that cannot be used directly in clinical practice, but can be used in the preparation of the compounds of the present invention and removed in subsequent processes.

[0018] Neurodegenerative diseases generally refer to diseases characterized by global or systemic neuronal damage or death, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, motor neuron disease, spinocerebellar type I, II and III, amyotrophic lateral sclerosis (ALS), schizophrenia, Lewy body dementia and frontotemporal dementia.

[0019] The methods and medicaments of the present invention are particularly suitable for use in Alzheimer's disease, Parkinson's disease, Huntington's disease, especially Alzheimer's disease.

[0020] In one aspect of the present invention, the compound of formula I is selected from:

[0021] 2-(Benzoylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide;

[0022] 2-(Benzoylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide;

[0023] 2-(Benzoylamino)-N-(4-methyl-3-nitrophenyl)-1,3-selenazole-5-carboxamide;

[0024] 2-(Indole-3-acetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0025] 2-(Indole-3-acetylamino)-N-(4-methylphenyl)-1,3-selenazole-5-carboxamide;

[0026] 2-(4-Methylphenylacetylamino)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide;

[0027] 2-(4-Methylphenylacetylamino)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide;

[0028] 2-(Benzoylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0029] 2-(3-Indolepropionylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0030] 2-(3-Indolecarboxamido)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide;

[0031] 2-(3-Indolepropionylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide;

[0032] 2-(4-Methylphenylacetylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide;

[0033] 2-(4-Methylphenylacetylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide;

[0034] 2-(4-Methylphenylacetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0035] 2-(4-Methylphenylacetylamino)-N-(4-methylphenyl)-1,3-selenazole-5-carboxamide;

[0036] 2-(3-Indoleacetylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0037] 2-(3-Indoleacetylamino)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide;

[0038] 2-(3-Indoleacetylamino)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide;

[0039] 2-(3-Indoleacetylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide;

[0040] 2-(3-Indoleacetylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide;

[0041] 2-(Benzoylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0042] 2-(Benzoylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0043] 2-(Benzoylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide;

[0044] 2-(2-Pyrrolylcarboxamido)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide;

[0045] 2-(2-Pyrrolylcarboxamido)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide;

[0046] 2-(Benzoylamino)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide;

[0047] 2-(4-(phenylmethyl)benzamido)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide;

[0048] 2-(Benzoylamino)-N-(2-naphthyl)-1,3-selenazole-5-carboxamide;

[0049] 2-(4-(phenylmethyl)benzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0050] 2-(3-phenylpropionylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0051] 2-(Heptanoylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0052] 2-(3-phenylpropionylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0053] 2-(Heptanoylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0054] 2-(Heptanoylamino)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide;

[0055] 2-(4-methoxybenzamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0056] 2-(4-Chlorobenzamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0057] 2-(Heptanoylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0058] 2-(3-phenylpropionylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0059] 2-(4-Chlorobenzamido)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0060] 2-(2-Chlorobenzamido)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0061] 2-(4-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0062] 2-(3-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0063] 2-(2-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0064] 2-(2-phenylacetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide;

[0065] 2-(2-phenylacetylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0066] 2-(Thiophene-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0067] 2-(Thiophene-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide;

[0068] 2-(Thiophene-3-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0069] 2-(Thiophene-3-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide;

[0070] 2-(Furan-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide;

[0071] 2-(Furan-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0072] 2-(Furan-2-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0073] 2-(1H-pyrrole-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide;

[0074] 2-(1H-pyrrole-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide;

[0075] 2-(Thiophene-2-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0076] 2-(Thiophene-3-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide;

[0077] N-(5-(m-methylphenylcarbamoyl)-1,3-selenazole-2-yl)-pyridinecarboxamide;

[0078] N-(5-(2,4-dimethylphenylcarbamoyl)-1,3-selenazole-2-yl)-pyridinecarboxamide;

[0079] 2-(Furan-2-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide;

[0080] 2-(Thiophene-2-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide; and

[0081] 2-(Thiophene-3-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide.

[0082] Suitable pharmaceutically acceptable salts of the compounds of formula I of the present invention are, for example, acid addition salts of the compounds of formula I, for example acid addition salts formed with inorganic or organic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, trifluoroacetic acid, citric acid or maleic acid); or ammonium salts, or salts formed with organic bases (such as methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine).

[0083] Suitable pharmaceutically acceptable solvates of the compounds of formula I of the present invention are, for example, hydrates, such as hemihydrate, monohydrate, dihydrate or trihydrate or optional combinations thereof.

[0084] The compounds of the invention may be administered in the form of a prodrug, which is a compound that is cleaved in the human or animal body to release the compound of the invention.

[0085] The inventors unexpectedly found that the compound of formula I or its pharmaceutically acceptable salt, solvate or prodrug has a neuroprotective effect and can significantly inhibit the activity of excessive aggregation of Aβ amyloid in model animals. Therefore, the compound of formula I or its pharmaceutically acceptable salt, solvate or prodrug of the present invention can be used to treat neurodegenerative diseases or to prepare related drugs.

[0086] Neurodegenerative diseases generally refer to diseases characterized by global or systemic neuronal damage or death, including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, motor neuron disease, spinocerebellar type I, II and III, amyotrophic lateral sclerosis (ALS), schizophrenia, Lewy body dementia and frontotemporal dementia.

[0087] The methods and medicaments of the present invention are particularly suitable for use in Alzheimer's disease, Parkinson's disease, Huntington's disease, especially Alzheimer's disease.

[0088] The compound of general formula I used in the present invention can be prepared by the following method (the synthesis of compound 4 in the flow chart is taken as an example):

[0089]

[0090] In one aspect of the present invention, a pharmaceutical composition is provided, which comprises a compound of formula I as defined above or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable excipient, such as a diluent or carrier, mixed therewith. The pharmaceutical composition is used for treating neurodegenerative diseases.

[0091] The pharmaceutical composition of the present invention can be obtained by conventional methods using conventional pharmaceutical excipients well known in the art. For example, the excipients that the composition intended for oral use may contain are one or more colorants, sweeteners, flavoring agents and / or preservatives. As used herein, the term "pharmaceutically acceptable carrier, diluent or excipient" refers to pharmaceutical excipients commonly used in the pharmaceutical industry, such as those listed in Luo Mingsheng et al., "Compendium of Pharmaceutical Excipients", Sichuan Science and Technology Press, 1995.

[0092] The pharmaceutical compositions of the present invention may be in a form suitable for oral administration (e.g., tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), in a form suitable for topical use (e.g., creams, ointments, gels, or aqueous or oily solutions or suspensions), in a form suitable for administration by inhalation (e.g., finely divided powders or liquid aerosols), in a form suitable for administration by insufflation (e.g., finely divided powders), or in a form suitable for parenteral administration (e.g., sterile aqueous or oily solutions for intravenous, subcutaneous, intraperitoneal or intramuscular administration, or suppositories for rectal administration).

[0093] The dosage and method of use of the compounds of the present invention depend on many factors, including the patient's age, weight, sex, natural health, nutritional status, activity strength of the compound, time of administration, metabolic rate, severity of the disease, and subjective judgment of the treating physician. The preferred dosage is between 0.001 and 100 mg / kg body weight / day, more preferably 0.01 mg / kg to 50 mg / kg body weight / day, and more preferably 0.1 mg / kg to 25 mg / kg body weight / day, and the optimal dosage is 1 mg / kg to 10 mg / kg body weight / day. If necessary, the effective daily dose can be divided into multiple doses for the purpose of administration; therefore, a single-dose composition may contain this amount or its sub-doses to constitute a daily dose. The frequency of administration of the above-mentioned compound of formula I can be determined according to the experience of the clinician and factors such as the patient's age, weight, sex, general health, and the type and severity of the disease, for example, once a day, twice, three times, four times, five times, etc., or once every two days, once every three days, once every one week, once every two weeks, etc.

[0094] According to another aspect of the present invention, there is provided use of the compound of formula I described above or a pharmaceutically acceptable salt, solvate or prodrug thereof in the preparation of a medicament for treating (or preventing) a neurodegenerative disease. DETAILED DESCRIPTION

[0095] The essential content and beneficial effects of the present invention will be further described below in conjunction with the examples. The examples are only used to illustrate the present invention but not to limit the present invention.

[0096] The melting point of the compound was determined by RY-1 melting point instrument, and the thermometer was not calibrated. The mass spectrum was determined by Micromass ZabSpec high-resolution mass spectrometer (resolution 1000). 1H NMR was determined by JNM-ECA-400 superconducting NMR instrument, with an operating frequency of 1H NMR 400 MHz and 13C NMR 100 MHz.

[0097] Example 1 2-(Benzoylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide

[0098]

[0099] Mix 54.4g of methyl chloroacetate and 110ml of dry toluene, cool, and add 31.6g of methyl formate when the temperature drops to 0℃. When the internal temperature drops to -10℃~-5℃, add 28.2g of 97% sodium methoxide, react at 5℃ for 4h, and then react at room temperature for 3h. Finally, 28.15g of yellow oil is obtained, which is the crude product of α-chloroformyl methyl acetate. Take 76g (1mol) of thiourea and dissolve it in 400ml of anhydrous ethanol. Slowly add 141.90 (1mol) of iodomethane. After the addition is complete, control the temperature at about 40℃, react until the solution is clear to stop the reaction, cool and stand, crystallize, filter, and obtain 89.01g of white crystals, which is methyl isothiourea. In a 1000ml three-necked flask, cool with nitrogen, add 7.27g of sodium borohydride and 13.63g of selenium powder in an ice bath, and stir evenly. Then, add 250ml of anhydrous ethanol slowly and then quickly. After the addition, react in an ice bath for 0.5h, then add 170ml of anhydrous ethanol to dissolve 30.22g of methylisothiourea solution, then add 14.77g of anhydrous sodium carbonate, reflux for 2h, and react at room temperature for 20h. After the reaction is over, add 34ml of glacial acetic acid to the reaction solution, pass nitrogen to drive out the generated hydrogen selenide and methylisothiourea gas, add a tail gas absorption device, 900ml of 5% lead acetate solution, and add the time for 2-3 hours. After that, filter, evaporate the filtrate under reduced pressure, and stop when the remaining 80ml-100ml is dried. Filter to obtain the filter cake, which is the product selenourea, 30.10g of crude product. Take 23.6 g of the newly prepared selenourea and 27.7 g of the crude product of methyl α-chloroformylformate and dissolve them in 500 ml of water, heat and react at 50°C for 2 h, stop the reaction, adjust the pH to 9 with aqueous ammonia, extract with ethyl acetate, dry with anhydrous magnesium sulfate, let stand, filter with suction, concentrate the filtrate, and purify the residue by silica gel column chromatography (methanol: dichloromethane = 1:300) to obtain 6.8 g of brown-yellow solid, which is methyl 2-amino-1,3-selenazole-5-carboxylate. Take 4.99g of 2-t-butyloxyformamide-1,3-selenazole-5-carboxylic acid and dissolve it in 100ml of 1,4-dioxane solution. Stir, then add 10ml of 1,4-dioxane dissolved 9.57g of gt-Boc anhydride, add 0.025g of DMAP to promote the reaction. When the reaction is complete, add 6ml of 5mol / l sodium hydroxide. After saponification, concentrate it to dryness, dissolve the residue with water, and then precipitate it with hydrochloric acid. Filter to obtain a brown-yellow solid. After drying, weigh 6.08g, which is 2-t-butyloxyformamide-1,3-selenazole-5-carboxylic acid. Add 6.0g of 2-t-butyloxyformamido-1,3-selenazole-5-carboxylic acid into a 250ml three-necked flask, add about 30ml of anhydrous dichloromethane, most of it is insoluble, add 4.78g of phenyl dichlorophosphate under ice bath condition after 5 minutes, no change, add 2.26g of p-bromoaniline after 15 minutes, react for 1 hour, add 6.88g of triethylamine dropwise, a small amount of white smoke is generated, stir at room temperature for about 6 hours, and then finish.After the reaction is completed, the reaction solution is washed with dilute hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride solution in turn, and the organic layer is dried with anhydrous sodium sulfate. After that, the organic layer is evaporated to dryness, mixed, and passed through a chromatography column, and the column is passed with an eluent of methanol: dichloromethane = 1:300, and finally 4.92g of light yellow solid is obtained, which is 2-t-butoxyformamide-5-(4-bromophenyl)-1,3-selenazole-carboxamide. 4.89g of 2-t-butoxyformamide-5-(4-bromophenyl)-1,3-selenazole-carboxamide is added to a 100ml eggplant-shaped bottle, and about 15ml of anhydrous dichloromethane is added. Part of it is insoluble. 12.54g of trifluoroacetic acid is added dropwise at room temperature, and the yellow turbid liquid immediately becomes clear and becomes a brown-red liquid. The reaction is carried out for about 6 hours. After the reaction is completed, the reaction solution is washed with saturated sodium bicarbonate, water, and saturated sodium chloride solution in turn, and the organic layer is dried with anhydrous sodium sulfate. After that, the organic layer was evaporated to dryness, mixed, and passed through a chromatography column, and the eluent was methanol: dichloromethane = 1:300 (1% ammonia water was added). Finally, 1.07g of light yellow solid was obtained, which was 2-amino-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide. 0.66g of benzoic acid was added to a 250ml eggplant-shaped bottle, and 5ml of anhydrous refined tetrahydrofuran was added to completely dissolve it. After 5min, 1.24g of dichlorophenyl phosphate was added, and after stirring for about 15min, 1.54g of 2-amino-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide was added. After 1h, 1.79g of triethylamine was added and stirred at room temperature for about 6h. After the reaction was completed, the reaction solution was washed with dilute hydrochloric acid, saturated sodium bicarbonate, and saturated sodium chloride solution in turn, and the organic layer was dried with anhydrous sodium sulfate. The organic layer was then evaporated to dryness, mixed, and passed through a chromatography column using an eluent of methanol: dichloromethane = 1:300 to obtain 0.50 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 δ7.53-7.59(m,4H); δ7.70-7.72(m,3H); δ8.15-8.17(d,2H); δ8.44(s,1H); δ10.31(s,1H); δ1D13.22(s,1H). MS(TOF)448.2(M-).

[0100] Example 2 2-(Benzoylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide

[0101]

[0102] The method of Example 1 was adopted, except that the p-bromoaniline was replaced by 3-fluoroaniline to obtain 0.25 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6)δ6.93-6.96(t,1H); δ7.73-7.43(m,1H); δ7.49-7.51(d,1H); δ7.56-7.60(t,2H); δ7 .66-δ7.72(m,2H); δ8.15-8.17(d,2H); δ8.45(s,1H); δ10.37(s,1H); δ13.17(s,1H). MS(TOF)390.2(M+).

[0103] Example 3 2-(Benzoylamino)-N-(4-methyl-3-nitrophenyl)-1,3-selenazole-5-carboxamide

[0104]

[0105] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 4-methyl-3-nitroamine to obtain 0.38 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.55(S,3H);δ7.49-7.51(d,1H);δ7.56-7.60(t,2H);δ7.66-7.69(t,1H);δ7.94-7.97 (m,1H); δ8.15-8.17(d,2H); δ8.46(d,1H); δ8.48(d,1H); δ10.53(s,1H); δ13.18(s,1H). MS(TOF)431.3(M+).

[0106] Example 4 2-(Indole-3-acetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0107]

[0108] The method of Example 1 was adopted, except that p-bromoaniline was replaced by o-methylaniline and benzoic acid was replaced by 3-indoleacetic acid to obtain 0.43 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.22-2.26(s,3H); δ3.93(s,2H); δ6.98-7.02(t,1H); δ7.07-7.11(t,1H); δ7.12-7.15(d,2H); δ7.30-7.31 (s,1H); δ7.36-7.38(d,1H); δ7.55-7.59(t,3H); δ8.13(s,1H); δ10.05(s,1H); δ11.00(s,1H); δ12.86(s,1H). MS(TOF)439.3(M+).

[0109] Example 5 2-(Indole-3-acetylamino)-N-(4-methylphenyl)-1,3-selenazole-5-carboxamide

[0110]

[0111] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-methylaniline and benzoic acid was replaced by indole-3-acetic acid to obtain 0.32 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.27(s,3H); δ3.93(s,2H); δ7.42-7.45(m,3H); δ7.55-7.67(m,5H); δ7.89-7.91(dd,1H); δ8.06-8.07(dd,1H); δ8.67(s,1H); δ8.83-8.85(d,1H); δ9.00-9.02(d,1H); δ11.04(s,1H). MS(TOF)439.3(M+).

[0112] Example 6 2-(4-Methylphenylacetylamino)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide

[0113]

[0114] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 4-methoxyaniline and benzoic acid was replaced by p-methylphenylacetic acid to obtain 0.39 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0115] δ2.28(s,3H); δ3.73(s,3H); δ3.78(s,2H); δ6.90-6.92(d,2H); δ7.14-7.16(d,2H); δ 7.21-7.23(d,2H); δ7.57-7.60(d,2H); δ8.29(s,1H); δ10.03(s,1H); δ12.86(s,1H). MS(TOF)430.2(M+).

[0116] Example 7 2-(4-Methylphenylacetylamino)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide

[0117]

[0118] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-tert-butylaniline and benzoic acid was replaced by p-methylphenylacetic acid to obtain 0.47 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ1.27(s,9H); δ2.28(s,3H); δ3.78(s,2H); δ7.14-7.16(d,2H); δ7.21-7.23(d,2H); δ7.34-7.36(d,2H); δ7.59-7.61(d,2H); δ8.33(s,1H); δ10.08(s,1H); δ12.87(s,1H). MS(TOF)456.2(M+).

[0119] Example 8 2-(Benzoylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0120]

[0121] The method of Example 1 was adopted, except that p-bromoaniline was replaced with 2,4-dimethylaniline to obtain 0.31 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.49(s,3H); δ2.50(s,3H); δ7.09(s,2H); δ7.18-7.20(d,1H); δ7.54-7.59 (t,2H); δ7.65-7.69(t,1H); δ8.14-8.16(d,2H); δ8.37(s,1H); δ9.78(s,1H). MS(TOF)400.2(M+).

[0122] Example 9 2-(3-Indolepropionylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0123]

[0124] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 2-chloro-6-methylaniline and benzoic acid was replaced by 3-indolepropionic acid to obtain 0.25 g of a light yellow solid.

[0125] 1 H-NMR (400 MHz, DMSO-d 6)δ2.23(s,3H); δ2.85-2.89(t,2H); δ3.05-3.07(t,2H); δ6.98-7.00(t,1H); δ7.05-7.07(t,1H); δ7.11-7.12(d,1H) ; δ7.26-7.34(m,3H); δ7.39(m,1H); δ7.56-7.58(d,1H); δ8.31(s,1H); δ9.95(s,1H); δ10.80(s,1H); δ12.70(s,1H). MS(TOF)487.3(M+).

[0126] Example 10 2-(3-Indolecarboxamido)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide

[0127]

[0128] The method of Example 1 was adopted, except that the benzoic acid was replaced with 3-indolecarboxylic acid to obtain 10 mg of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 ) δ7.15-7.18(m,2H); δ7.46-7.52(m,3H); δ7.75-7.78(m,2H); δ8.29-8.30(d,2H); δ9.84(s,1H); δ11.78(s,1H). MS(TOF)490.2(M+).

[0129] Embodiment 11 2-(3-Indolepropionylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide

[0130]

[0131] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 3-fluoroaniline and benzoic acid was replaced by 3-indolepropionic acid to obtain 0.28 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0132] δ2.86-2.89(t,2H); δ3.05-3.09(t,2H); δ6.90-7.00(m,2H); δ7.05-7.12(m,2H); δ7.32-7.41(m,2H); δ7.47-7.4 9(d,1H); δ7.56-7.58(d,1H); δ7.66-7.70(m,1H); δ8.33(s,1H); δ10.30(s,1H); δ10.80(s,1H); δ12.73(s,1H);. MS(TOF)457.2(M+).

[0133] Example 12 2-(4-Methylphenylacetylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide

[0134]

[0135] The method of Example 1 was adopted, except that the benzoic acid was replaced with p-methylphenylacetic acid to obtain 0.26 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0136] δ2.28(s,3H); δ3.78(s,2H); δ7.14-7.16(d,2H); δ7.21-7.23(d,2H); δ7.51-7 .53(d,2H); δ7.67-7.69(d,2H); δ8.34(s,1H); δ10.25(s,1H); δ12.91(s,1H). MS(TOF)478.0(M+).

[0137] Embodiment 13 2-(4-Methylphenylacetylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide

[0138]

[0139] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 3-fluoroaniline and benzoic acid was replaced by p-methylphenylacetic acid, to obtain 0.15 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.28(s,3H); δ3.79(s,2H); δ6.91-6.92(m,1H); δ7.14-7.23(m,4H); δ7.37- 7.48(m,2H); δ7.65-7.68(d,1H); δ8.35(s,1H); δ10.31(s,1H); δ12.93(s,1H). MS(TOF)418.5(M+).

[0140] Embodiment 14 2-(4-Methylphenylacetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0141]

[0142] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 2-methylaniline and benzoic acid was replaced by p-methylphenylacetic acid to obtain 0.48 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0143] δ2.22(s,3H); δ2.28(s,3H); δ3.78(s,2H); δ7.14-7.23(m,8H); δ8.29(s,1H); δ9.79(s,1H); δ12.87(s,1H). MS(TOF)414.4(M+).

[0144] Embodiment 15 2-(4-Methylphenylacetylamino)-N-(4-methylphenyl)-1,3-selenazole-5-carboxamide

[0145]

[0146] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-methylaniline and benzoic acid was replaced by p-methylphenylacetic acid to obtain 0.54 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 ) δ2.28 (s, 6H); δ3.78 (s, 2H); δ7.13-7.16 (m, 4H); δ7.21-7.23 (d, 2H); δ7.56-7.58 (d, 2H); δ8.32 (s, 1H); δ10.07 (s, 1H); δ12.88 (s, 1H). MS(TOF)414.4(M+).

[0147] Example 16 2-(3-Indoleacetylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0148]

[0149] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 2,4-dimethylaniline and benzoic acid was replaced by 3-indoleacetic acid to obtain 0.37 g of a light yellow solid.

[0150] 1 H-NMR (400 MHz, DMSO-d 6)δ2.17(s,3H);δ2.27(s,3H);δ3.93(s,2H);δ6.98-7.02(t,2H);δ7.07-7.09(d,1H);δ7.10-7,11(s,1H);δ7.15-7.17(d,1H) ); δ7.30-7.31(d,1H); δ7.36-7.38(d,1H); δ7.57-7.59(d,1H); δ8.27(s,1H); δ9.70(s,1H); δ11.00(s,1H); δ12.83(s,1H). MS(TOF)453.2(M+).

[0151] Embodiment 17 2-(3-Indoleacetylamino)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide

[0152]

[0153] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-methoxyaniline and benzoic acid was replaced by 3-indoleacetic acid to obtain 0.26 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0154] δ3.36(s,3H); δ3.93(s,2H); δ6.90-7.10(m,4H); δ7.30-7.38(m,2H); δ7.57 -7.59(d,3H); δ8.29(s,1H); δ10.02(s,1H); δ11.00(s,1H); δ12.84(s,1H). MS(TOF)455.2(M+).

[0155] Embodiment 18 2-(3-Indoleacetylamino)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide

[0156]

[0157] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-tert-butylaniline and benzoic acid was replaced by 3-indoleacetic acid to obtain 0.32 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0158] δ1.24-1.27(s,9H); δ3.93(s,2H); δ6.98-7.02(t,1H); δ7.07-7.10(t,1H); δ7.30-7.38 (m,4H); δ7.57-7.61(t,3H)δ8.32(s,1H); δ10.07(s,1H); δ11.00(s,1H); δ12.86(s,1H). MS(TOF)481.1(M+).

[0159] Embodiment 19 2-(3-Indoleacetylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide

[0160]

[0161] The method of Example 1 was adopted, except that the benzoic acid was replaced with 3-indoleacetic acid to obtain 0.27 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ3.94(s,2H); δ6.98-7.02(t,1H); δ7.07-7.10(t,1H); δ7.30-7.31(d,1H); δ7.36-7.38 (d,1H); δ7.51-7.69(m,5H); δ8.34(s,1H); δ10.24(s,1H); δ11.00(s,1H); δ12.91(s,1H). MS(TOF)503.1(M+).

[0162] Embodiment 20 2-(3-Indoleacetylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide

[0163]

[0164] The method of Example 1 was adopted, except that p-bromoaniline was replaced by 3-fluoroaniline and benzoic acid was replaced by 3-indoleacetic acid to obtain 0.19 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0165] δ3.94(s,2H); δ6.91-6.94(t,1H); δ6.98-7.02(t,1H); δ7.07-7.11(t,1H); δ7.31(d,1H); δ7.34-7.40(m,2H); δ7.46 -7.48(d,1H); δ7.57-7.59(d,1H); δ7.65-7.68(d,1H); δ8.35(s,1H); δ10.30(s,1H); δ11.01(s,1H); δ12.92(s,1H). MS(TOF)443.3(M+).

[0166] Embodiment 21 2-(Benzoylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0167]

[0168] The method of Example 1 was adopted, except that p-bromoaniline was replaced with 2-chloro-6-methylaniline to obtain 0.23 g of a white solid. 1 H-NMR (400 MHz, DMSO-d 6 )δ2.25(s,3H); δ7.25-7.31(m,2H); δ7.40-7.42(d,1H); δ7.56-7.59(t,2H); δ7.6 5-7.69(t,1H); δ8.15-8.17(d,2H); δ8.42(s,1H); δ10.01(s,1H); δ13.24(s,1H);. MS(TOF)420.2(M+).

[0169] Embodiment 22 2-(Benzoylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0170]

[0171] The method of Example 1 was adopted, except that the p-bromoaniline was replaced by o-methylaniline to obtain 0.35 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0172] δ2.25(s,3H); δ7.17-7.23(m,2H); δ7.27-7.29(d,1H); δ7.33-7.35(d,1H); δ7.55-7.59(t ,2H); δ7.65-7.67(t,1H); δ8.15-8.17(d,2H); δ8.39(s,1H); δ9.85(s,1H); δ13.17(s,1H). MS(TOF)386.2(M+).

[0173] Embodiment 23 2-(Benzoylamino)-N-(4-bromophenyl)-1,3-selenazole-5-carboxamide

[0174]

[0175] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-methylaniline to obtain 0.33 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0176] δ2.28(s,3H); δ7.15-7.17(d,2H); δ7.55-7.69(m,5H); δ8.15-8.16(d,2H); δ8.42(s,1H); δ10.12(s,1H); δ13.20(s,1H);. MS(TOF)386.2(M+).

[0177] Embodiment 24 2-(2-Pyrrolylcarboxamido)-N-(4-methoxyphenyl)-1,3-selenazole-5-carboxamide

[0178]

[0179] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-methoxyaniline and benzoic acid was replaced by 2-pyrrolecarboxylic acid to obtain 0.36 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0180] δ3.75(s,3H); δ6.23-6.24(s,1H); δ6.92-6.95(d,2H); δ7.13(s,1H); δ7.38(s,1H) ; δ7.60-7.62(d,2H); δ8.35(s,1H); δ10.03(s,1H); δ12.04(s,1H); δ12.73(s,1H). MS(TOF)391.2(M+).

[0181] Embodiment 252-(2-Pyrrolylcarboxamido)-N-(4-tert-butylphenyl)-1,3-selenazole-5-carboxamide

[0182]

[0183] The method of Example 1 was adopted, except that p-bromoaniline was replaced by p-tert-butylaniline and benzoic acid was replaced by 2-pyrrolecarboxylic acid to obtain 0.43 g of a light yellow solid. 1 H-NMR (400 MHz, DMSO-d 6 )

[0184] δ1.28(s,9H); δ6.23-6.24(s,1H); δ7.12-7.13(s,1H); δ7.35-7.38(d, 3H); δ7.62-7.64(d,2H); δ8.38(s,1H); δ10.08(s,1H); δ12.05(s,1H). MS(TOF)417.3(M+).

[0185] Embodiment 26 2-(Benzoylamino)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide

[0186]

[0187] The method of Example 1 was adopted, except that the p-bromoaniline was replaced with 3,4-methylenedioxyaniline to obtain 0.06 g of yellow solid with a yield of 14.5%.

[0188] 1H-NMR (400MHz, DMSO-d6) δ6.01 (s, 2H), δ6.89-6.91 (d, 1H, J = 8.40Hz), δ7.12-7.15 (q, 1H, J = 10.36Hz), δ7.40-7.41 (d, 1H, J = 2.24Hz), δ7 .51-7.59(m,2H),δ7.65-7.69(t,1H),δ8.15-8.16(d,2H,J=7.28Hz)δ,8.42(s,1H),δ10.15(s,1H),13.26(s,1H)ESI-MSm / z:415.01[MH]+.

[0189] Embodiment 27 2-(4-(Phenylmethyl)benzamido)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide

[0190]

[0191] The synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 4-(methylphenyl)benzoic acid, and the p-bromoaniline was replaced by 3,4-methylenedioxyaniline to obtain 0.031 g of yellow solid with a yield of 12.8%.

[0192] 1H-NMR (400MHz, DMSO-d6) δ4.04 (s, 2H), δ6.01-6.02 (s, 2H), δ6.89-6.91 (d, 1H, J = 8.68Hz), δ7.10-7.12 (q, 1H, J = 10.68Hz), δ7.21-7.33(m,5H), δ7.38-7.43(m,3H), δ8.07-8.09(d,2H,J=8.44Hz), δ8.37(s,1H), δ10.09(s,1H), δ13.17-13.26(s,1H). ESI-MSm / z: 505.05[M+H]+.

[0193] Embodiment 28 2-(Benzoylamino)-N-(2-naphthyl)-1,3-selenazole-5-carboxamide

[0194]

[0195] The synthesis method of Example 1 was adopted, and the p-bromoaniline was replaced with 2-naphthylamine to obtain 0.07 g of a milky white solid with a yield of 12.2%. 1H-NMR (400 MHz, DMSO-d6), δ7.44-7.68 (m, 5H), δ7.78-7.93 (m, 4H, J=8.68H), δ8.17-8.18 (d, 2H, J=7.28Hz), δ8.39-8.40 (s, 1H), δ8.52 (s, 1H), δ10.41 (s, 1H) δ,13.23 (s, 1H). ESI-MS m / z: 421.03 [M+H]+.

[0196] Embodiment 29 2-(4-(Phenylmethyl)benzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0197]

[0198] The synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 4-(phenylmethyl)benzoic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline to obtain 0.03 g of product with a yield of 5.9%. 1H-NMR (400 MHz, DMSO-d6) δ2.25 (s, 3H), 4.05 (s, 2H) δ7.22-7.34 (m, 7H), δ7.40-7.42 (d, 3H, J=8.12 Hz), δ8.08-8.10 (d, 2H, J=8.12), δ8.41 (s, 1H), δ9.96 (s, 1H) δ, 13.11 (s, 1H). ESI-MS m / z: 509.04 [M+H]+.

[0199] Embodiment 30 2-(3-phenylpropionylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0200]

[0201] The synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 3-phenylpropionic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline, and finally 0.29 g of light yellow solid was obtained with a yield of 30.5%.

[0202] δ2.23(s,3H), δ2.80-2.84(t,2H,J=8.08Hz), δ2.94-2.98(t,2H,J=7.40Hz), δ7.18-7.31(m,7 H), δ7.39-7.41 (dd, 1H, J1=1.76Hz, J2=7.40Hz), δ8.30 (s, 1H), δ9.95 (s, 1H), δ12.69 (s, 1H). ESI-MS m / z: 447.03[M+H]+.

[0203] Embodiment 31 2-(Heptanoylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0204]

[0205] The synthesis method of Example 1 was adopted, and the benzoic acid was changed to n-heptanoic acid, and the p-bromoaniline was changed to 2,4-dimethyl-aniline to obtain 0.33 g of the product with a yield of 47.7%. 1H-NMR (400 MHz, DMSO-d6) δ0.85-0.88 (t, 3H), δ1.27 (s, 8H), δ1.59-1.63 (m, 2H), δ2.18 (s, 3H), δ2.27 (s, 3H), δ6.99-7.02 (d, 1H, J=8.12 Hz), δ7.07 (s, 1H), δ7.16-7.18 (d, 1H, J=8.16 Hz), δ8.26 (s, 1H), δ9.70 (s, 1H), δ12.58 (s, 1H). ESI-MS m / z: 407.11 [M+H]+.

[0206] Embodiment 32 2-(3-phenylpropionylamino)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0207]

[0208] The synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 3-phenylpropionic acid, and the p-bromoaniline was replaced by 2,4-dimethylaniline to obtain 0.25 g of a milky white solid with a yield of 46.5%.

[0209] 1H-NMR (400MHz, DMSO-d6) δ2.18(s,3H), δ2.28(s,3H), δ2.79-2.83(t,2H,J=7.04Hz), δ2.93-2.97(t,2H,J=7.28H z), δ7.00-7.02 (d, 1H, J = 7.88Hz), δ7.08 (s, 1H), δ7.16-7.31 (m, 6H), δ8.26 (s, 1H), δ9.71 (s, 1H), δ12.64 (s, 1H). ESI-MS m / z: 427.08[M+H]+.

[0210] Embodiment 33 Synthesis of 2-(Heptanoylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide (LWL0335)

[0211]

[0212] The general synthesis method of Example 1 was adopted, and the benzoic acid was changed to n-heptanoic acid, and the p-bromoaniline was changed to 2-chloro-6-methylaniline to obtain 0.09 g of the product with a yield of 21.1%. mp: 274°C-276°C, 1H-NMR (400MHz, DMSO-d6) δ0.87 (s, 3H), δ1.28 (s, 8H), δ1.60-1.63 (s, 2H), δ2.23-2.26 (s, 3H), δ7.26-7.29 (m, 2H), δ7.39-7.41 (d, J=7.28Hz), δ8.31-8.34 (s, 1H), δ9.95 (s, 1H), δ12.65 (s, 1H). ESI-MS m / z: 427.06 [M+H]+.

[0213] Embodiment 34 2-(Heptanoylamino)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide

[0214]

[0215] The general synthesis method of Example 1 was adopted, and the benzoic acid was changed to n-heptanoic acid, and the p-bromoaniline was changed to 3,4-methylenedioxyaniline to obtain 0.16 g of the product with a yield of 37.8%. 1H-NMR (400 MHz, DMSO-d6) δ0.85-0.88 (t, 3H), δ1.27-1.31 (s, 8H), δ1.59-1.63 (m, 2H), δ6.01 (s, 2H), δ6.88-6.90 (d, 1H, J=8.4 Hz), δ7.08-7.11 (dd. 1H, J1=1.96 Hz, J2=8.44 Hz), δ7.36-7.37 (d, 1.96 Hz), δ8.27 (s, 1H), δ10.04 (s, 1H), δ12.62 (s, 1H). ESI-MS m / z: 423.07 [M+H]+.

[0216] Embodiment 35 2-(4-methoxybenzamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0217]

[0218] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by p-methoxybenzoic acid, and p-bromoaniline was replaced by 2,4-dimethyl-aniline to obtain 25 mg of the product with a yield of 5%. 1H-NMR (400 MHz, DMSO-d6) δ2.21 (s, 3H), δ2.28 (s, 3H), δ3.86 (s, 3H), δ7.00-7.01 (d, 1H, J=8.12 Hz), δ7.09-7.11 (d, 1H, J=8.12 Hz), δ7.17-7.19 (d, 1H, J=7.84 Hz), δ8.15-8.17 (d, 2H, J=8.96 Hz), δ8.43 (s, 1H), δ9.88 (s, 1H), δ13.00 (s, 1H). ESI-MS m / z: 429.06 [M+H]+.

[0219] Embodiment 36 2-(4-Chlorobenzamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0220]

[0221] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by p-chlorobenzoic acid, and p-bromoaniline was replaced by 2,4-dimethyl-aniline to obtain 95 mg of the product with a yield of 21.9%. 1H-NMR (400 MHz, DMSO-d6) δ2.20 (s, 3H), δ2.29 (s, 3H), δ7.01-7.03 (d, 1H, J=8.12 Hz), δ7.09 (s, 1H), δ7.18-7.20 (d, 1H, J=8.12 Hz), δ7.63-7.65 (d, 2H, J=8.68 Hz), δ8.16-8.18 (d, 2H, J=8.6 Hz), δ8.37 (s, 1H), δ9.78 (s, 1H), δ13.22 (s, 1H). ESI-MS m / z: 433.01 [M+H]+.

[0222] Embodiment 37 2-(Heptanoylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0223]

[0224] The synthesis method of Example 1 was adopted, and the benzoic acid was changed to n-heptanoic acid, and the p-bromoaniline was changed to 2-methylaniline to obtain 0.15 g of a light yellow solid with a yield of 26.9%. 1H-NMR (400 MHz, DMSO-d6) δ0.85-0.88 (t, 3H, J=13.44 Hz), δ1.23-1.31 (s, 8H), δ1.60-1.63 (m, 2H), δ2.23 (s, 3H), δ7.15-7.23 (m, 2H), δ7.26-7.32 (m, 2H), δ8.28 (s, 1H), δ9.77 (s, 1H), δ12.61 (s, 1H). ESI-MS m / z: 393.10 [M+H]+.

[0225] Embodiment 38 2-(3-phenylpropionylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0226]

[0227] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 3-phenylpropionic acid, and the p-bromoaniline was replaced by 2-methylaniline to obtain 0.19 g of yellow solid with a yield of 32.1%. 1H-NMR (400 MHz, DMSO-d6) δ2.23 (s, 3H), δ2.80-2.83 (t, 2H, J=8.04 Hz), δ2.94-2.97 (t, 2H, J=7.2 Hz), δ7.17-7.32 (m, 9H), δ7.39-7.41 (d, J=7.28 Hz), δ8.28 (s, 1H), δ9.79 (s, 1H), δ12.67 (s, 1H). ESI-MS m / z: 413.06 [M+H]+.

[0228] Embodiment 39 2-(4-Chlorobenzamido)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0229]

[0230] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 4-chlorobenzoic acid, and the p-bromoaniline was replaced by 2-methylaniline to obtain 0.15 g of the product with a yield of 25.2%. 1H-NMR (400 MHz, DMSO-d6) δ2.25 (s, 3H), δ7.16-7.35 (m, 4H), δ7.64-7.66 (d, 2H, J=8.4 Hz), δ8.16-8.18 (d, 2H, J=8.44 Hz), δ8.39 (s, 1H), δ9.86 (s, 1H), δ13.31 (s, 1H). ESI-MS m / z:418.99[M+H]+.

[0231] Embodiment 40 2-(2-Chlorobenzamido)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0232]

[0233] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-chlorobenzoic acid, and the p-bromoaniline was replaced with 2-methylaniline to obtain 30 mg of the product with a yield of 5.1%. 1H-NMR (400MHz, DMSO-d6) δ2.25 (s, 3H), δ7.13-7.35 (m, 4H), δ7.48-7.52 (m1H), 7.58-7.63 (m, 2H), δ7.70-7.72 (d, 2H, J=6.72Hz), δ8.37 (s, 1H), δ9.89 (s, 1H), δ13.27 (s, 1H). ESI-MS m / z:418.99[M+H]+。

[0234] Embodiment 41 2-(4-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0235]

[0236] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 4-chlorobenzoic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline to obtain 55 mg of the product with a yield of 12.1%. 1H-NMR (400 MHz, DMSO-d6) δ2.25 (s, 3H), δ7.27-7.30 (m, 2H), δ7.40-7.42 (d, 1H, J=7.56 Hz), δ7.64-7.66 (d, 2H, J=8.68 Hz), δ8.17-8.19 (d, 2H, J=8.68 Hz), δ8.41 (s, 1H), δ10.03 (s, 1H), δ13.33 (s, 1H). ESI-MS m / z:452.96[M+H]+.

[0237] Embodiment 42 2-(3-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0238]

[0239] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 3-chlorobenzoic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline to obtain 80 mg of the product with a yield of 17.7%. 1H-NMR (400 MHz, DMSO-d6) δ2.25 (s, 3H), δ7.25-7.30 (m, 2H), δ7.39-7.41 (d, 1H, J=7.28 Hz), δ7.56-7.60 (m, 1H), δ7.68-7.70 (d, 1H, J=7.56 Hz), δ8.09-8.11 (d, 1H, J=7.56 Hz), δ8.20 (s, 1H), δ8.42 (s, 1H), δ10.02 (s, 1H), δ13.19 (s, 1H). ESI-MS m / z: 452.96 [M+H]+.

[0240] Embodiment 43 2-(2-Chlorobenzamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0241]

[0242] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-chlorobenzoic acid, and the p-bromoaniline was replaced with 2-chloro-6-methylaniline to obtain 188 mg of the product with a yield of 41.5%. 1H-NMR (400MHz, DMSO-d6) δ2.26 (s, 3H), δ7.26-7.30 (m, 2H), δ7.41-7.43 (d, 1H, J=7.28Hz), δ7.48-7.52 (t, 1H, J=7.28Hz), δ7.57-7.64 (m, 2H), δ7.70-7.72 (d, 1H, J=7.56Hz), δ8.40 (s, 1H), δ10.06 (s, 1H), δ13.29 (s, 1H). ESI-MS m / z:452.96[M+H]+.

[0243] Embodiment 44 2-(2-phenylacetylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide

[0244]

[0245] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by phenylacetic acid, and the p-bromoaniline was replaced by 2-methylaniline to obtain 0.17 g of the product with a yield of 47.9%. 1H-NMR (400 MHz, DMSO-d6), δ2.23 (s, 3H), δ3.84 (s, 2H), δ7.14-7.23 (m, 2H), δ7.26-7.35 (m, 7H), δ830 (s, 1H), δ9.80 (s, 1H), δ12.91 (s, 1H). ESI-MS m / z: 399.05 [M+H]+.

[0246] Embodiment 45 2-(2-phenylacetylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0247]

[0248] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by phenylacetic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline to obtain 49 mg of the product with a yield of 11.3%. 1H-NMR (400 MHz, DMSO-d6) δ2.24 (s, 3H), δ3.87 (s, 2H), δ7.25-7.33 (m, 3H), δ7.36-7.37 (d, 4H, J=3.64 Hz), δ7.39-7.42 (m, 1H), δ835 (s, 1H), δ9.99 (s, 1H), δ12.96 (s, 1H). ESI-MS m / z: 433.01 [M+H]+.

[0249] Embodiment 46 2-(Thiophene-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0250]

[0251] The general synthesis method of Example 1 was used, and the benzoic acid was replaced by 2-thiophenecarboxylic acid, and the p-bromoaniline was replaced by 2,4-dimethylaniline to obtain 30 mg of light yellow solid powder with a yield of 9.06%, mp: 219°C-220°C. MS[M+]+=406.0m / e,1H NMR(400Hz,DMSO-d6)δ13.29(s,1H),9.76(s,1H),8.34(s,1H),8.19(s,1H),7.98(s,1H),7.28-7.26(t,1H ,J=8.6HZ),7.19-7.17(d,1H,J=7.8HZ),7.08(s,1H),7.02-7.00(d,1H,J=8.1HZ),2.28(s,3H),2.19(s,3H)

[0252] Embodiment 47 2-(Thiophene-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide

[0253]

[0254] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 2-thiophenecarboxylic acid, and the p-bromoaniline was replaced by 3-methylaniline to obtain a light yellowish white solid powder with a yield of 15%, mp: 254°C-256°C. MS[M+]+=392.0m / e,1HNMR(400Hz,DMSO-d6)δ13.35(s,1H),10.13(s,1H),8.42(s,1H),7.99(s,2H),7.56(s,1H),7.52- 7.50(d,1H,J=8.1HZ),7.27-7.25(d,1H,J=7.3HZ),7.23-7.21(d,1H,J=7.9HZ),6.93-6.91(d,1H,J=7.5HZ),2.30(s,3H)

[0255] Embodiment 48 2-(Thiophene-3-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0256]

[0257] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced by 3-thiophenecarboxylic acid, and the p-bromoaniline was replaced by 2,4-dimethylaniline to obtain a light white solid powder with a yield of 15%, mp: 253°C-255°C. MS[M+]+=406.2,1H NMR (400Hz, DMSO-d6) δ13.08(s,1H),9.76(s,1H),8.68(s,1H),8.36(s,1H),7.77-7.73(d,1H,J=16.8HZ),7.72-7. 71(m,1H,J=4.7HZ),7.19-7.17(d,1H,J=8.9HZ),7.08(s,1H),7.02-7.00(d,1H,J=8.1HZ),2.28(s,3H),2.19(s,3H)

[0258] Embodiment 49 2-(Thiophene-3-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide

[0259]

[0260] The general synthesis method of Example 1 was used, except that the benzoic acid was replaced by 3-thiophenecarboxylic acid and the p-bromoaniline was replaced by 3-methylaniline to obtain a light yellowish white solid powder with a yield of 21.4% and mp: 264°C-265°C. MS[M+]+=392.2m / e,1HNMR(400Hz,DMSO-d6)δ13.07(s,1H),10.08(s,1H),8.68(s,1H),8.41(s,1H),7.77(s,1H),7.72( s,1H),7.55(s,1H),7.51-7.49(d,1H,J=8.4HZ),7.24-7.20(t,1H,J=15.4HZ),6.92-6.90(d,1H,J=7.6HZ),2.30(s,3H)

[0261] Embodiment 50 2-(Furan-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide

[0262]

[0263] The general synthesis method of Example 1 was used, except that the benzoic acid was replaced by 2-furancarboxylic acid and the p-bromoaniline was replaced by 3-methylaniline to obtain 0.180 g of a yellow-white foamy solid with a yield of 48.13%, mp: 290°C-291°C. MS[M+]+=376.0m / e,1H NMR (400Hz, DMSO-d6) δ13.24(s,1H),10.10(s,1H),8.34(s,1H),8..40-8.38(d,1H,J=5.6HZ),7.55(s,1H),7. 51-7.49(d,1H,J=8.7HZ),7.24-7.21(t,1H,J=15.7HZ),6.93-6.91(d,1H,J=7.6HZ),6.76(s,1H),2.30(s,3H)

[0264] Embodiment 51 2-(Furan-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0265]

[0266] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-furancarboxylic acid, and the p-bromoaniline was replaced with 2,4-dimethylaniline to obtain a light yellow solid powder with a yield of 72.17%, mp: 234°C-237°C. MS [M+] + = 376.0 m / e, 1H NMR (400 Hz, DMSO-d6) δ 13.20 (s, 1H), 9.76 (s, 1H), 8.33 (s, 1H), 8.05 (s, 1H), 7.89 (s, 1H), 7.19-7.17 (d, 1H, J = 8.8 Hz), 7.08 (s, 1H), 7.02-7.00 (d, 1H, J = 7.7 Hz), 6.76 (s, 1H), 2.28 (s, 3H), 2.19 (s, 3H)

[0267] Embodiment 52 2-(Furan-2-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0268]

[0269] The general synthesis method of Example 1 was used, and the benzoic acid was replaced by 2-furancarboxylic acid, and the p-bromoaniline was replaced by 2-chloro-6-methylaniline to obtain a yellow solid powder with a yield of 83.36%, mp: 252°C-254°C.

[0270] MS[M+]+=410.1m / e,1H NMR(400Hz,DMSO-d6)δ13.24(s,1H),10.00(s,1H),8.37(s,1H),8.05(s,1H),7.70(s,1H),7.42-7.3 9(m,1H,J=9.2Hz),7.30-7.28(m,1H,J=9.5Hz),7.26-7.24(d,1H,J=7.5Hz),6.76(s,1H),2.24(s,3H)

[0271] Embodiment 53 2-(1H-Pyrrole-2-carboxamido)-Nm-methylphenyl-1,3-selenazole-5-carboxamide

[0272]

[0273] The general synthesis method of Example 1 was used, except that the benzoic acid was replaced by 1H-2-pyrrolcarboxylic acid and the p-bromoaniline was replaced by 3-methylaniline to obtain a light yellowish white solid powder with a yield of 21.4% and mp: 230°C-232°C. MS[M+]+=374.3m / e,1H NMR(400Hz,DMSO-d6)δ12.19(s,1H),11.71(s,1H),10.76(s,1H),10.14(s,1H),7.62(s,1H),7.57-7.55(d,1 H,J=8.3Hz),7.26-7.22(t,1H,J=16.5Hz),6.71(s,1H),6.13-6.11(m,1H,J=8.3Hz),2.29(s,3H),2.19(s,3H)

[0274] Embodiment 54 2-(1H-pyrrole-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide

[0275]

[0276] The general synthesis method of Example 1 was used, and the benzoic acid was replaced by 1H-2-pyrrolcarboxylic acid, and the p-bromoaniline was replaced by 2,4-dimethylaniline to obtain a light yellow-green solid powder with a yield of 26.92%, mp: 263°C-264°C. MS[M+]+=389.1m / e,1H NMR (400Hz, DMSO-d6) δ12.75(s,1H),12.03(s,1H),9.70(s,1H),8.31(s,1H),7.38(s,1H),7.19-7.17(d,1H,J=8. 2Hz),7.12(s,1H),7.07(s,1H),7.02-7.00(d,1H,J=8.1Hz),6.24-6.22(m,1H,J=3.9Hz),2.28(s,3H),2.19(s,3H)

[0277] Embodiment 55 2-(Thiophene-2-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0278]

[0279] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-thiophenecarboxylic acid, and the p-bromoaniline was replaced with 2-chloro-6-methylaniline to obtain a yellow solid powder with a yield of 33.91%, mp: 210°C-213°C. MS [M+] + = 426.0m / e, 1H NMR (400Hz, DMSO-d6) δ 13.30 (s, 1H), 10.00 (s, 1H), 8.38 (s, 1H), 8.01 (s, 1H), 7.41-7.39 (d, 1H, J = 7.6Hz), 7.30-7.28 (m, 2H, J = 9.2Hz), 7.26-7.24 (m, 1H, J = 7.5Hz), 2.24 (s, 3H)

[0280] Embodiment 56 2-(Thiophene-3-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide

[0281]

[0282] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 3-thiophenecarboxylic acid, and the p-bromoaniline was replaced with 2-chloro-6-methylaniline to obtain a yellow-white solid powder with a yield of 73.5%, mp: 239°C-241°C. MS [M+] + = 425.8m / e, 1H NMR (400Hz, DMSO-d6) δ 13.12 (s, 1H), 10.00 (s, 1H), 8.70 (s, 1H), 8.41 (s, 1H), 7.78 (s, 1H), 7.73 (s, 1H), 7.41-7.39 (m, 1H, J = 7.2Hz), 7.30-7.28 (m, 1H, J = 9.8Hz), 7.26-7.24 (m, 1H, J = 7.5Hz), 2.24 (s, 3H)

[0283] Embodiment 57 N-(5-(m-methylphenylcarbamoyl)-1,3-selenazole-2-yl)-pyridinecarboxamide

[0284]

[0285] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-pyridinecarboxylic acid, and the p-bromoaniline was replaced with 3-methylaniline to obtain a light milky white solid powder with a yield of 15%, mp: 259°C-261°C. MS [M+] + = 387.0 m / e, 1H NMR (400 Hz, DMSO-d6) δ 12.64 (s, 1H), 10.20-10.13 (d, 1H, J = 24.7 Hz), 8.80-8.78 (d, 1H, J = 4.5 Hz), 8.42-8.40 (d, 1H, J = 8.4 Hz), 8.24-8.20 (t, 1H, J = 15.1 Hz), 8.14-8 .10(m,1H,J=17.1Hz),7.76-7.73(m,1H,J=14.2Hz),7.55(s,1H),7.52-7.50(d,1H ,J=8.9Hz),7.25-7.21(m,1H,J=15.7Hz),6.93-6.91(d,1H,J=7.3Hz),2.31(s,3H)

[0286] Embodiment 58 N-(5-(2,4-dimethylphenylcarbamoyl)-1,3-selenazole-2-yl)-pyridinecarboxamide

[0287]

[0288] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-pyridinecarboxylic acid, and the p-bromoaniline was replaced with 2,4-dimethylaniline to obtain a light milky white solid powder with a yield of 10%, mp: 235°C-236°C. MS [M+] + = 401.0 m / e, 1H NMR (400 Hz, DMSO-d6) δ 13.24 (s, 1H), 10.00 (s, 1H), 8.37 (s, 1H), 8.05 (s, 1H), 7.70 (s, 1H), 7.42-7.39 (m, 1H, J = 9.2 Hz), 7.30-7.28 (m, 1H, J = 9.5 Hz), 7.26-7.24 (d, 1H, J = 7.5 Hz), 6.76 (s, 1H), 2.24 (s, 3H)

[0289] Embodiment 59 2-(Furan-2-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide

[0290]

[0291] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-furancarboxylic acid, and p-bromoaniline was replaced with p-fluoroaniline to obtain a yellow solid powder with a yield of 83.36%, mp: 311°C-312°C. MS [M+] + = 401.1m / e, 1H NMR (400Hz, DMSO-d6) δ 13.25 (s, 1H), 10.30-10.23 (d, 1H, J = 30.5Hz), 8.38-8.37 (d, 1H, J = 5.6Hz), 8.05 (s, 1H), 7.74-7.70 (m, 3H, J = 14.0Hz), 7.22-7.17 (m, 2H, J = 17.7Hz), 6.76 (s, 1H)

[0292] Embodiment 60 2-(Thiophene-2-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide

[0293]

[0294] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 3-thiophenecarboxylic acid, and p-bromoaniline was replaced with p-fluoroaniline to obtain a light milky white flocculent solid powder with a yield of 29.46%, mp: 282°C-284°C. MS [M+] + = 396.1m / e, 1HNMR (400Hz, DMSO-d6) δ 13.12 (s, 1H), 10.30-10.24 (d, 1H, J = 27.2Hz), 8.68 (s, 1H), 8.41-8.39 (d, 1H, J = 10.3Hz), 7.74-7.72 (m, 4H, J = 8.9Hz), 7.22-7.18 (m, 2H, J = 17.7Hz)

[0295] Embodiment 61 2-(Thiophene-3-carboxamido)-N-(4-fluorophenyl)-1,3-selenazole-5-carboxamide

[0296]

[0297] The general synthesis method of Example 1 was adopted, and the benzoic acid was replaced with 2-thiophenecarboxylic acid, and p-bromoaniline was replaced with p-fluoroaniline to obtain a light milky white flocculent solid powder with a yield of 38.60%, mp: 286°C-289°C. MS [M+] + = 396.1m / e, 1HNMR (400Hz, DMSO-d6) δ 13.35 (s, 1H), 10.24 (s, 1H), 8.40 (s, 1H), 8.29 (s, 1H), 8.02 (s, 1H), 7.74-7.71 (m, 2H, J = 9.0Hz), 7.27 (s, 1H), 7.22-7.18 (t, 2H, J = 17.9Hz)

[0298] Example 62 Cultivation and paralysis count of CL4176 nematodes

[0299] The nematode CL4176 is an Aβ1-42 transgenic AD model nematode. Under the condition of 16°C, the nematodes grow and develop normally. When the temperature rises to 25°C, Aβ oligomers are produced in the nematode muscles, and the nematodes begin to paralyze and gradually become paralyzed. The same concentration (10μM) of compound-dosed group and control group were cultured at 16°C for 48 hours and then transferred to 25°C for 36 hours, and then the number of paralyzed CL4176 nematodes in each group was counted. Counting and observation were performed every 2 hours until 50 hours. When the nematode no longer crawls after being touched, and only the head swings to produce fan-shaped marks, it is defined as nematode paralysis. Paralysis rate = paralysis count / total nematode count in this group × 100%. The results are shown in Table 1.

[0300] Table 1 Effects of compounds on improving paralysis of CL4176 nematodes caused by Aβ

[0301] Example Paralysis rate Example Paralysis rate Example Paralysis rate 1 28% 22 15% 43 36% 2 36% 23 42% 44 27% 3 44% 24 36% 45 33% 4 54% 25 27% 46 54% 5 42% 26 17% 47 24% 6 55% 27 42% 48 18% 7 34% 28 20% 49 58% 8 35% 29 25% 50 60% 9 18% 30 55% 51 39% 10 51% 31 33% 52 47% 11 43% 32 53% 53 55% 12 57% 33 37% 54 14% 13 60% 34 21% 55 11% 14 40% 35 25% 56 10% 15 53% 36 27% 57 51% 16 37% 37 30% 58 36% 17 50% 38 42% 59 46% 18 43% 39 28% 60 41% 19 39% 40 60% 61 52% 20 12% 41 54% Control group 85% 21 13% 42 52%

[0302] The results showed that the paralysis rate of the control group was 85%, and most of the compounds showed a significant paralysis improvement effect, with the paralysis rate ranging from 10-60%, which was significantly better than the control group.

[0303] Example 63 Detection of Aβ deposition in thioflavin T nematodes

[0304] Thioflavin T is a dye that specifically binds to amyloid protein deposition. CL4176 induces Aβ amyloid protein deposition under high temperature. The drug-added group (10μM) and the control group were subjected to Thioflavin T fluorescence staining. The fluorescence observed under a fluorescence microscope only came from Thioflavin T bound to amyloid protein. The fluorescence content of different groups was used to determine the Aβ protein deposition content.

[0305] 100-200 nematodes of the test group were transferred to a 1.5mL centrifuge tube with M9 buffer, placed on ice for 1min to settle the worms, centrifuged at 4200r / min for 2min, and the supernatant was removed. The M9 buffer was repeatedly rinsed three times to remove excess bacteria. Each tube was fixed with 150μL of cell tissue fixative at 4℃ for 24h. Rinse repeatedly with 1mL of PBS buffer for 3 times. Add 150μL of 5% β-mercaptoethanol, 125mM Tris-HCl (PH=7.4) and 1% TritonX-100, transfer to 37℃ and incubate for 24h. Rinse three times with PBS buffer containing 0.1% Tween20, discard the supernatant, and stain with 0.125% Thioflavine T / 50% ethanol for 2-3min. Decolorize with 50% ethanol for 2-3min. After rinsing with PBS buffer, prepare slides for observation, sedimentation rate = staining area of ​​drug group / staining area of ​​control group × 100%. The results are shown in Table 2.

[0306] Table 2 Effects of compounds on improving Aβ deposition

[0307]

[0308]

[0309] The results showed that most of the compounds showed a significant effect in reducing Aβ deposition, with the deposition rate ranging from 20-80%, which was significantly better than the control group.

[0310] Example 64 Detection of ROS content in H2DCF-DA nematodes

[0311] Increased ROS content can induce oxidative damage in the body. In studies using nematodes as materials, a large number of studies have confirmed that excessive deposition of ROS is the main factor that causes aging and induces senile diseases. The nematodes in each treatment group (10 μM) were picked into a 1.5 mL centrifuge tube containing M9 buffer, with 200-300 nematodes per tube, centrifuged to remove the supernatant, and rinsed with M9 buffer three times before transferring the nematodes to a 1 mL M9 buffer system containing 100 μM H2DCF-DA fluorescent probe, and incubated at room temperature in the dark for 2 hours. The incubated nematodes were rinsed with M9 three times to remove the influence of the H2DCF-DA fluorescent probe in the solution. The nematodes were picked into a 96-well plate containing 200 μL M9 buffer, 20 nematodes were transferred to each well, and six parallel replicates were performed in each group. The fluorescence intensity of each group of nematodes was detected using a fluorescent microplate reader. (Excitation wavelength 485 nm, emission wavelength 528 nm.) Fluorescence intensity ratio = fluorescence intensity of drug-added group / fluorescence intensity of control group × 100%. The results are shown in Table 3.

[0312] Table 3 Results of compounds improving ROS content

[0313]

[0314]

[0315] The results showed that most of the compounds could significantly reduce the amount of ROS in CL4176 nematodes, with the fluorescence intensity ratio ranging from 85-45%, which was significantly stronger than the control group.

[0316] The above is an explanation of the present invention and cannot be regarded as a limitation of the present invention. Unless otherwise noted, the practice of the present invention will use the conventional techniques of organic chemistry, polymer chemistry, biotechnology, etc., and it is obvious that the present invention can also be realized in other ways except that it is particularly described in the above description and embodiments. Other aspects and improvements within the scope of the present invention will be apparent to those skilled in the art to which the present invention belongs. According to the teachings of the present invention, many changes and variations are feasible, and therefore they are within the scope of the present invention.

Claims

1. Use of the following compounds or pharmaceutically acceptable salts thereof in the preparation of drugs for treating neurodegenerative diseases: 2-(3-Indolepropionylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide; 2-(3-Indoleacetylamino)-N-(3-fluorophenyl)-1,3-selenazole-5-carboxamide; 2-(Benzoylamino)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide; 2-(Benzoylamino)-N-(2-methylphenyl)-1,3-selenazole-5-carboxamide; 2-(Benzoylamino)-N-(3,4-methylenedioxyphenyl)-1,3-selenazole-5-carboxamide; 2-(Thiophene-3-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide; 2-(1H-pyrrole-2-carboxamido)-N-(2,4-dimethylphenyl)-1,3-selenazole-5-carboxamide; 2-(Thiophene-2-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide; and 2-(Thiophene-3-carboxamido)-N-(2-chloro-6-methylphenyl)-1,3-selenazole-5-carboxamide.

2. The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, motor neuron disease, spinocerebellar type I, II and III, amyotrophic lateral sclerosis, schizophrenia, Lewy body dementia or frontotemporal dementia.

3. The use according to claim 2, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease or Huntington's disease. The use according to claim 3 , wherein the neurodegenerative disease is Alzheimer's disease.